Acinetobacter baumannii strain:MRSN110819
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA950448 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Six Extensively-drug Resistant Bacteria Cultured from an Injured Ukrainian National
| PRJNA950451 | ENA
Project description:Six Extensively-drug Resistant Bacteria Cultured from an Injured Ukrainian National
| PRJNA950450 | ENA
Project description:Six Extensively-drug Resistant Bacteria Cultured from an Injured Ukrainian National
| PRJNA950449 | ENA
Project description:Phylogenomics of Colistin-Resistant, Extensively Drug-Resistant Acinetobacter baumannii.
| PRJNA417158 | ENA
Project description:We analyzed the extracellular proteome of colistin-resistant Korean Acinetobacter baumannii (KAB) strains to identify proteome profiles that can be used to characterize extensively drug-resistant KAB strains.
2020-05-27 | PXD015959 | Pride
Project description:Extensively Drug Resistant Acinetobacter baumannii WGS: Clinical Isolates from Jordan
| PRJNA739752 | ENA
Project description:The bacterial pathogen, Acinetobacter baumannii, is a leading cause of drug-resistant infections. Here, we investigated the potential of developing nanobodies that specifically recognize A. baumannii over other Gram-negative bacteria. Through generation and panning of a synthetic nanobody library, we identified several potential lead candidates. We demonstrate how incorporation of next generation sequencing analysis can aid in selection of lead candidates for further characterization. Using monoclonal phage display, we validated the binding of several lead nanobodies to A. baumannii. Subsequent purification and biochemical characterization revealed one particularly robust nanobody that broadly and specifically bound A. baumannii compared to other common drug resistant pathogens. These findings support the potentially for nanobodies to selectively target A. baumannii and the identification of lead candidates for possible future diagnostic and therapeutic development.
2023-06-21 | GSE202972 | GEO
Project description:Background: Acinetobacter baumannii is one of the most dangerous multidrug-resistant pathogens worldwide. Currently, 50-70% of clinical isolates of A. baumannii are extensively drug-resistant (XDR) and available antibiotic options against A. baumannii infections are limited. There are still needs to discover specific de facto bacterial antigenic proteins that could be effective vaccine candidates in human infection. With the growth of research in recent years, several candidate molecules have been identified for vaccine development. So far, there is no public health authorities approved vaccine against A. baumannii. Methods: The purpose of this study was to identify immunodominant vaccine candidate proteins that can be immunoprecipitated specifically with patients’ IgGs. Relaying on hypothesis that IgGs of infected person have capacity to capture immunodominant bacterial proteins. Herein, outer membrane and secreted proteins of sensitive and drug resistant A. baumannii were captured by using IgGs obtained from patient and healthy control sera and were identified by LC-MS/MS analysis. Results: By using subtractive proteomic approach, we determined 34 unique proteins which were captured only in drug-resistant A. baumannii strain via patient sera. After extensive evaluation of predicted epitope regions, solubility, membrane transverse characteristics, and structural properties, we selected several notable vaccine candidates. Conclusion: We identified vaccine candidate proteins that triggered de facto response of human immune system against the antibiotic-resistant A. baumannii. Precipitation of bacterial proteins via patient immunoglobulins was a novel approach to identify the proteins which have potential to trigger to response in patient immune system.
2022-11-02 | PXD037507 | Pride
Project description:Sequence multi-drug resistant Acinetobacter baumannii strains for ARLG-ICMR
| PRJNA384065 | ENA